Stock Events

Stock Events

Vanda Pharmaceuticals 

€4.48
56
-€0.08-1.84% 07:46 Today

Statistics

Day High
4.51
Day Low
4.48
52W High
8.25
52W Low
3.68
Volume
-
Avg. Volume
-
Mkt Cap
270.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2025
Q1 2026
Q2 2026
Next
-2.01
-1.51
-1.01
-0.5
Expected EPS
-0.580635
Actual EPS
N/A

Financials

-101.26%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
187.56MRevenue
-189.92MNet Income

Analyst Ratings

12.14Average Price Target
The highest estimate is 15.18.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VM4.STU. It's not an investment recommendation.
Microsoft
9
MSFT
Apple
8
AAPL
Tesla
8
TSLA
Amazon
8
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals competes directly with Vanda in the CNS and mental health drug market, particularly in treatments for schizophrenia and Parkinson’s disease psychosis.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes competes in the area of schizophrenia and bipolar disorder treatments, areas where Vanda Pharmaceuticals also operates.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries offers a broad range of generic and specialty drugs that compete across several of Vanda’s therapeutic areas.
Jazz Pharmaceuticals
JAZZ
Mkt Cap15.87B
Jazz Pharmaceuticals has a portfolio that includes CNS treatments, directly competing with Vanda’s offerings in sleep disorders and psychiatric drugs.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma targets genetic diseases and cancers but its focus on novel drug discovery and development in areas that can overlap with Vanda’s interests makes it a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a wide range of products that compete with Vanda Pharmaceuticals in several areas, including treatments for skin conditions and cancer.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a diverse pharmaceutical product line that can compete with Vanda Pharmaceuticals in the areas of oncology and acute hospital care.
Pfizer
PFE
Mkt Cap159.36B
Pfizer offers a broad portfolio of drugs and vaccines, including treatments for psychiatric disorders, competing with Vanda Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a diverse range of pharmaceutical products that compete with Vanda Pharmaceuticals, especially in the oncology and cardiovascular segments.

About

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Show more...
CEO
Mihael H. Polymeropoulos
Employees
533
Country
United States
ISIN
US9216591084
WKN
000A0JJT3

Listings

STU
DE
VM4.STU
F
DE
VM4.F
LSE
GB
0LKB.LSE
XNAS
US
VNDA

0 Comments

Share your thoughts

FAQ

What is Vanda Pharmaceuticals stock price today?▼
The current price of VM4.STU is €4.48 EUR — it has decreased by -1.84% in the past 24 hours. Watch Vanda Pharmaceuticals stock price performance more closely on the chart.
What is Vanda Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Vanda Pharmaceuticals stocks are traded under the ticker VM4.STU.
Is Vanda Pharmaceuticals stock price growing?▼
VM4.STU stock has fallen by -1.19% compared to the previous week, the month change is a -2.78% fall, over the last year Vanda Pharmaceuticals has showed a +12.05% increase.
What is Vanda Pharmaceuticals market cap?▼
Today Vanda Pharmaceuticals has the market capitalization of 270.99M
When is the next Vanda Pharmaceuticals earnings date?▼
Vanda Pharmaceuticals is going to release the next earnings report on November 04, 2026.
What were Vanda Pharmaceuticals earnings last quarter?▼
VM4.STU earnings for the last quarter are -0.9 EUR per share, whereas the estimation was -0.5 EUR resulting in a -78.54% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Vanda Pharmaceuticals revenue for the last year?▼
Vanda Pharmaceuticals revenue for the last year amounts to 187.56M EUR.
What is Vanda Pharmaceuticals net income for the last year?▼
VM4.STU net income for the last year is -189.92M EUR.
How many employees does Vanda Pharmaceuticals have?▼
As of September 04, 2026, the company has 533 employees.
In which sector is Vanda Pharmaceuticals located?▼
Vanda Pharmaceuticals operates in the Health & Wellness sector.
When did Vanda Pharmaceuticals complete a stock split?▼
Vanda Pharmaceuticals has not had any recent stock splits.
Where is Vanda Pharmaceuticals headquartered?▼
Vanda Pharmaceuticals is headquartered in WASHINGTON, United States.